Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfecti...(assay developmentlibrary screening and t...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent
Date:11/3/2008
assay development, library screening, and transfection services (http://www.altogen.com/support.htm).
'/>"/>
| SOURCE Altogen Biosystems Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
2. Enigma Diagnostics Announces Patent Licence With Applied Biosystems
3. Ahram Biosystems Completes Development of a Palm-Size Portable PCR Device
4. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
5. Open Biosystems Open Access RNAi Program Adopted by University of Copenhagen and University of Queensland
6. Open Biosystems Open Access RNAi Program Adopted by Harvard Medical School and University of North Carolina
7. Sigma-Aldrich, Oxford BioMedica and Open Biosystems Settle Patent Dispute Over Use of LentiVector Technology in Research Reagents
8. Microfluidic Systems Announces Agreements With Applied Biosystems and United Technologies Hamilton Sundstrand Division for Production of Bioagent Autonomous Networked Detector System
9. Primera Biosystems Raises $21 Million in Series B Private Round
10. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
11. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
Post Your Comments:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3
[0] AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology[0] Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer[0] EUCODIS Bioscience Appoints Thomas Fischer as New CEO[0] AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
Other Biology Technology:NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd 2Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting 2Korean Food and Drug Administration Approval for ActiPatch Achieved 2
Breaking Biology News(10 mins):White, but not pure 2White, but not pure 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6Stem cells battle for space 2Artielle ImmunoTherapeutics Announces Positive Results of Phase 1 Multiple Sclerosis Trial 4995 1Artielle ImmunoTherapeutics Announces Positive Results of Phase 1 Multiple Sclerosis Trial 4995 2Artielle ImmunoTherapeutics Announces Positive Results of Phase 1 Multiple Sclerosis Trial 4995 3Routine Testing Would Improve Herceptin Use in Breast Cancer 57020 1National Certification for Medical Interpreters Public Call for Final Written Pilot Exam 57018 1National Certification for Medical Interpreters Public Call for Final Written Pilot Exam 57018 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |